

# Alexey V Danilov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9317393/publications.pdf>

Version: 2024-02-01

159  
papers

3,231  
citations

212478

28  
h-index

214428

50  
g-index

161  
all docs

161  
docs citations

161  
times ranked

5640  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
2	The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. <i>Cancer Discovery</i> , 2019, 9, 910-925.	7.7	215
3	Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. <i>Nature Biotechnology</i> , 2022, 40, 527-538.	9.4	128
4	The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- $\kappa$ B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1576-1589.	3.2	108
5	Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. <i>Cancer</i> , 2018, 124, 3192-3200.	2.0	70
6	Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 846-854.	1.1	68
7	DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance. <i>PLoS ONE</i> , 2011, 6, e26815.	1.1	64
8	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	0.6	59
9	Cardiac non-Hodgkin's lymphoma: clinical characteristics and trends in survival. <i>European Journal of Haematology</i> , 2016, 97, 445-452.	1.1	55
10	Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 2810-2818.	3.2	46
11	Decitabine is an effective treatment of idiopathic myelofibrosis. <i>British Journal of Haematology</i> , 2009, 145, 131-132.	1.2	43
12	Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 734-736.	1.2	42
13	CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. <i>Cancer Research</i> , 2015, 75, 2029-2038.	0.4	40
14	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	2.0	40
15	Gossypol Increases Expression of the Pro-apoptotic BH3-only Protein NOXA through a Novel Mechanism Involving Phospholipase A2, Cytoplasmic Calcium, and Endoplasmic Reticulum Stress. <i>Journal of Biological Chemistry</i> , 2014, 289, 16190-16199.	1.6	39
16	Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1520-1532.	1.9	39
17	Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. <i>Blood Advances</i> , 2019, 3, 51-62.	2.5	39
18	Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. <i>Leukemia Research</i> , 2010, 34, 566-571.	0.4	38

#	ARTICLE	IF	CITATIONS
19	Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. <i>Journal of Clinical Apheresis</i> , 2015, 30, 308-310.	0.7	38
20	Molecular Pathogenesis of Chronic Lymphocytic Leukemia. <i>Current Molecular Medicine</i> , 2006, 6, 665-675.	0.6	37
21	Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future. <i>Clinical Therapeutics</i> , 2013, 35, 1258-1270.	1.1	37
22	Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2758-2766.	1.9	37
23	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
24	Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. <i>Oncotarget</i> , 2018, 9, 24576-24589.	0.8	36
25	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	1.9	36
26	Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. <i>PLoS ONE</i> , 2015, 10, e0143685.	1.1	32
27	Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1504-1514.	1.9	30
28	The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2014, 19, 201-209.	2.2	28
29	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 46-52.	0.6	28
30	A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in <i>TP53</i> . <i>British Journal of Haematology</i> , 2014, 167, 149-161.	1.2	27
31	SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, 1890-1900.	1.7	27
32	Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. <i>Leukemia</i> , 2021, 35, 156-168.	3.3	24
33	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
34	Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 461-465.	0.6	23
35	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	3.2	23
36	Differential control of G0 programme in chronic lymphocytic leukaemia: a novel prognostic factor. <i>British Journal of Haematology</i> , 2005, 128, 472-481.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Pro-apoptotic TP53 homolog p63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 590-602.	1.2	22
38	Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 501-503.	1.2	22
39	Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner. <i>Clinical Cancer Research</i> , 2021, 27, 4910-4922.	3.2	22
40	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	1.7	21
41	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
42	FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma. <i>Journal of Hematopathology</i> , 2013, 6, 11-18.	0.2	20
43	Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. <i>Cancer Biology and Therapy</i> , 2016, 17, 291-299.	1.5	20
44	Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. <i>American Journal of Hematology</i> , 2020, 95, E199-E203.	2.0	20
45	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. <i>British Journal of Haematology</i> , 2021, 193, 15-25.	1.2	20
46	Impact of Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia: A Retrospective Analysis. <i>Blood</i> , 2014, 124, 1312-1312.	0.6	20
47	Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2342-2353.	3.3	18
48	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	1.7	18
49	Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. <i>British Journal of Haematology</i> , 2021, 192, 720-728.	1.2	17
50	Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2010, 38, 1167-1177.	0.2	14
51	Cell Death Pathways in Lymphoid Malignancies. <i>Current Oncology Reports</i> , 2020, 22, 10.	1.8	14
52	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2862-2870.	0.6	13
53	The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	1.1	13
54	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	3.3	13

#	ARTICLE	IF	CITATIONS
55	Pevedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. <i>Oncotarget</i> , 2017, 8, 21128-21139.	0.8	12
56	Dual BTK/SYK inhibition with CG-806 (luxetininib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. <i>Cell Death and Disease</i> , 2022, 13, 246.	2.7	12
57	Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 302-309.	1.2	11
58	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
59	The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. <i>Blood Advances</i> , 2022, 6, 2701-2706.	2.5	11
60	CAR T-Cell Therapy in the Older Person: Indications and Risks. <i>Current Oncology Reports</i> , 2022, 24, 1189-1199.	1.8	11
61	Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia <i>in vivo</i> . <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 493-501.	1.1	10
62	Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 2946-2950.	0.6	10
63	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	0.6	10
64	A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 477-489.	1.9	9
65	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	0.6	9
66	Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1009-1012.	1.1	8
67	Targeting neddylation effectively antagonizes nuclear factor- $\kappa$ B in chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2015, 56, 1566-1569.	0.6	8
68	Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities – is there an optimal dose?. <i>Expert Review of Hematology</i> , 2017, 10, 707-718.	1.0	8
69	Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival. <i>Blood</i> , 2018, 132, 4146-4146.	0.6	8
70	Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells. <i>Blood</i> , 2016, 128, 289-289.	0.6	8
71	Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells. <i>Journal of Immunology</i> , 2017, 199, 1275-1282.	0.4	7
72	Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis. <i>Blood</i> , 2019, 134, 780-780.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 884-884.	0.6	7
74	Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2258-2260.	0.6	6
75	Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. <i>Haematologica</i> , 2021, 106, 2022-2025.	1.7	6
76	AIDS-related Burkitt lymphoma—A heterogeneous disease?. <i>Leukemia Research</i> , 2008, 32, 1939-1941.	0.4	5
77	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. <i>Leukemia Research</i> , 2020, 89, 106302.	0.4	5
78	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 8-18.	1.2	5
79	Neddylation and anti-tumor immunity. <i>Oncotarget</i> , 2021, 12, 2227-2230.	0.8	5
80	Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 481-488.	1.1	5
81	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2021, 39, 1099-1105.	1.2	5
82	Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 836-841.	1.1	5
83	Urticarial linear IgA bullous dermatosis (LABD) as a presenting sign of chronic lymphocytic leukemia (CLL). <i>JAAD Case Reports</i> , 2015, 1, 412-414.	0.4	4
84	A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. <i>British Journal of Haematology</i> , 2017, 178, 820-823.	1.2	4
85	Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK-981 Augments Interferon Signaling and Regulates T Cell Differentiation in Ex Vivo studies of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 1760-1760.	0.6	4
86	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. <i>Blood</i> , 2021, 138, 529-529.	0.6	4
87	Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. <i>Oncologist</i> , 2022, 27, 57-66.	1.9	4
88	MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 272-275.	1.2	3
89	Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia—response to Rider. <i>British Journal of Haematology</i> , 2016, 173, 327-328.	1.2	3
90	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3

#	ARTICLE	IF	CITATIONS
91	NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells. <i>Oncotarget</i> , 2021, 12, 2068-2074.	0.8	3
92	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	0.6	3
93	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	0.6	3
94	Outpatient Decitabine in Elderly Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 4144-4144.	0.6	3
95	A Novel Cyclin Dependent Kinase Inhibitor P1446A Induces Apoptosis Of Chronic Lymphocytic Leukemia B Cells. <i>Blood</i> , 2013, 122, 1636-1636.	0.6	3
96	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016, 128, 1785-1785.	0.6	3
97	A Phase I Trial of PI3KÎ±Î³ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL). <i>Blood</i> , 2021, 138, 3558-3558.	0.6	3
98	Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study. <i>Blood</i> , 2021, 138, 3726-3726.	0.6	3
99	Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia " PassÃ© Yet?. <i>HemaSphere</i> , 2019, 3, e275.	1.2	2
100	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 294-297.	1.1	2
101	Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 791-800.	0.6	2
102	Targeting Nedd8 Activating Enzyme Induces DNA Damage and Cell Cycle Arrest and Sensitizes Chronic Lymphocytic Leukemia (CLL) B-Cells to Alkylating Agents. <i>Blood</i> , 2014, 124, 4690-4690.	0.6	2
103	Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial. <i>Blood</i> , 2015, 126, 1498-1498.	0.6	2
104	A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML. <i>Blood</i> , 2021, 138, 3423-3423.	0.6	2
105	A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2021, 138, 2433-2433.	0.6	2
106	TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data. <i>Blood</i> , 2021, 138, 2488-2488.	0.6	2
107	Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S265-S266.	2.0	1
108	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 3135-3135.	0.6	1



#	ARTICLE	IF	CITATIONS
109	Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial. <i>Blood</i> , 2019, 134, 4312-4312.	0.6	1
110	SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 4295-4295.	0.6	1
111	Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. <i>Blood</i> , 2019, 134, 3491-3491.	0.6	1
112	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997.	0.6	1
113	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	0.6	1
114	ZAP-70 Disrupts Dipeptidyl Peptidase 2 (DPP2)-Regulated Quiescence in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2009, 114, 1251-1251.	0.6	1
115	Targeting Microenvironment-Mediated NF $\kappa$ B Activation With MLN4924, An Inhibitor Of The Nedd8-Activating Enzyme, In Chronic Lymphocytic Leukemia B Cells. <i>Blood</i> , 2013, 122, 2875-2875.	0.6	1
116	SYK Inhibition Disrupts the Cross-Talk Between B-Cell Activation Factor (BAFF) and B-Cell Receptor (BCR) and Thereby Antagonizes Mcl-1 in Chronic Lymphocytic Leukemia (CLL) B-Cells. <i>Blood</i> , 2016, 128, 303-303.	0.6	1
117	TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells. <i>Blood</i> , 2018, 132, 1867-1867.	0.6	1
118	Pevonedistat, a Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Induces Cell Cycle Deregulation, Anaphase Catastrophe, and Apoptosis in T-Cell Lymphoma Cells. <i>Blood</i> , 2018, 132, 1667-1667.	0.6	1
119	Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4317-4317.	0.6	1
120	An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 4716-4716.	0.6	1
121	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	0.6	1
122	Transcriptional Reprogramming of Super-Enhancer Associated Oncogenes Following Inhibition of Cyclin-Dependent Kinase-9 (CDK9) in Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2021, 138, 3493-3493.	0.6	1
123	Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 2643-2643.	0.6	1
124	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	0.6	1
125	MGA deletion Leads to Richter's Transformation Via NME1. <i>Blood</i> , 2021, 138, 252-252.	0.6	1
126	Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1407-1407.	0.6	1



#	ARTICLE	IF	CITATIONS
127	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq1 10.784314 rgBT /Ove	0.6	1
128	Acute inflammatory skin reaction during neutrophil recovery after antileukemic therapy. <i>Cutis</i> , 2016, 98, E13-E15.	0.4	1
129	A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 722-724.	0.6	1
130	Immunity in CLL: corrupt at inception?. <i>Blood</i> , 2022, 139, 2104-2105.	0.6	1
131	Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S23-S24.	2.0	0
132	New Targetable Pathways in Chronic Lymphocytic Leukemia (CLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S148-S150.	0.2	0
133	Improvements in Health-Related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	0
134	Dipeptidyl Peptidase 2 - A Pro-Survival Molecule in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 4964-4964.	0.6	0
135	Apoptosis in Response to Inhibition of Dipeptidyl Peptidase 2 (DPP2) Defines Low Risk Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 3094-3094.	0.6	0
136	p53 Homolog TAp63 elicits apoptosis in Chronic Lymphocytic Leukemia (CLL) B-Cells,. <i>Blood</i> , 2011, 118, 3894-3894.	0.6	0
137	B-Cell Receptor Signaling Suppresses TAp63-Induced Apoptosis Via PI3-K/mTOR Pathway and Upregulation of MiR-21 in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 562-562.	0.6	0
138	microRNA-21 Is Differentially Expressed in the Lymphoid Tissue and Modulated By Stromal Signaling in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1975-1975.	0.6	0
139	Pevedistat Sensitizes Diffuse Large B-Cell Lymphoma Cells to Death Receptor Ligand-Mediated Apoptosis. <i>Blood</i> , 2015, 126, 3994-3994.	0.6	0
140	Prognostic Markers in Cardiac Non-Hodgkin Lymphoma: A Retrospective Review. <i>Blood</i> , 2015, 126, 5007-5007.	0.6	0
141	Voruciclib Sensitizes High Risk Diffuse Large B Cell Lymphoma to BCL2 Inhibition Mediated Cell Death and Tumor Regression. <i>Blood</i> , 2016, 128, 4167-4167.	0.6	0
142	Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. <i>Blood</i> , 2017, 130, 683-683.	0.6	0
143	Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis. <i>Blood</i> , 2017, 130, 918-918.	0.6	0
144	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4153-4153.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias. <i>Blood</i> , 2018, 132, 214-214.	0.6	0
146	CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells. <i>Blood</i> , 2018, 132, 3503-3503.	0.6	0
147	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	0.6	0
148	Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 5344-5344.	0.6	0
149	Immunomodulatory Effects of Pevonedistat, a NEDD8-Activating Enzyme (NAE) Inhibitor, in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 2946-2946.	0.6	0
150	Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4848-4848.	0.6	0
151	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891.	0.6	0
152	Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis. <i>Blood</i> , 2019, 134, 3982-3982.	0.6	0
153	Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies. <i>Blood</i> , 2019, 134, 4313-4313.	0.6	0
154	Richter's Transformation after CD-19 Directed CAR-T Cells for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, 138, 1430-1430.	0.6	0
155	A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication. <i>Blood</i> , 2021, 138, 50-50.	0.6	0
156	Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD). <i>Blood</i> , 2021, 138, 1927-1927.	0.6	0
157	Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon Response and T Cell-Mediated Anti-Tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models. <i>Blood</i> , 2021, 138, 3719-3719.	0.6	0
158	METTL3 Dysregulates RNA Splicing by Translational Control of Splicing Factors via m 6A Modification in CLL. <i>Blood</i> , 2021, 138, 499-499.	0.6	0
159	Nedd8-Activating Enzyme Inhibition Enhances Anti-Tumor Immunity and PD1 Blockade in <i>In Vivo</i> lymphoma Models. <i>Blood</i> , 2021, 138, 2414-2414.	0.6	0